CLINICAL TRIAL SUMMARY

MDACC Study No:RTOG0825 (clinicaltrials.gov NCT No: NCT00884741)
Title:PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS BEVACIZUMAB VERSUS CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Principal Investigator:Mark R. Gilbert
Treatment Agent:Bevacizumab; Irinotecan; Temozolomide
Study Status:Closed
Study Description:The goal of this clinical research study is to find out if adding bevacizumab
to the combination of temozolomide and radiation will help to control
glioblastoma better than treatment with temozolomide and radiation alone.
Researchers will study if the genetic pattern in the tumor cells is related to
each participant's response to the bevacizumab and the overall outcome. The
safety of these 2 combination treatments will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Brain; CNS
Phase of Study:Phase III
Treatment Agents:Bevacizumab
Irinotecan
Temozolomide
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:NCI/RTOG
Return Visit:Every 2 weeks
Home Care:Patients will take temozolomide at home.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Mark R. Gilbert
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults